BDBM50384820 EPELSIBAN::GSK557296B

SMILES CC[C@H](C)[C@H]1N([C@@H](C(=O)N2CCOCC2)c2ccc(C)nc2C)C(=O)[C@H](NC1=O)C1Cc2ccccc2C1

InChI Key InChIKey=UWHCWRQFNKUYCG-UHFFFAOYSA-N

Data  4 KI  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 50384820   

TargetCytochrome P450 3A4(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50384820(GSK557296B | EPELSIBAN)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrateMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2013
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50384820(GSK557296B | EPELSIBAN)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human CYP3A4 using diethoxyfluorescein as substrateMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2013
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50384820(GSK557296B | EPELSIBAN)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human CYP2D6More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2013
Entry Details Article
PubMed
TargetCytochrome P450 2C19(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50384820(GSK557296B | EPELSIBAN)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human CYP2C19More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2013
Entry Details Article
PubMed
TargetCytochrome P450 2C9(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50384820(GSK557296B | EPELSIBAN)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human CYP2C9More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2013
Entry Details Article
PubMed
TargetCytochrome P450 1A2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50384820(GSK557296B | EPELSIBAN)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human CYP1A2More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2013
Entry Details Article
PubMed
TargetOxytocin receptor(Human)
Shanghai Hengrui Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50384820(GSK557296B | EPELSIBAN)
Affinity DataIC50: 9.20nMAssay Description:Antagonist activity at human OTR expressed in HEK293 cells assessed as decrease in calcium flux measured after 10 mins in presence of vasopressin by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetOxytocin receptor(Human)
Shanghai Hengrui Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50384820(GSK557296B | EPELSIBAN)
Affinity DataKi:  0.126nMAssay Description:Displacement of [3H]oxytocin from human oxytocin receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2013
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50384820(GSK557296B | EPELSIBAN)
Affinity DataKi:  3.98E+3nMAssay Description:Displacement of [3H]vasopressin from human vasopressin V2 receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2013
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50384820(GSK557296B | EPELSIBAN)
Affinity DataKi: >6.31E+3nMAssay Description:Displacement of [3H]vasopressin from human vasopressin V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2013
Entry Details Article
PubMed
TargetVasopressin V1b receptor(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50384820(GSK557296B | EPELSIBAN)
Affinity DataKi: >7.94E+3nMAssay Description:Displacement of [3H]vasopressin from human vasopressin V1b receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2013
Entry Details Article
PubMed